US Patent 5,475,034: Scope, Claim Strength, and US Landscape for Topical Ophthalmic Anti-Inflammatory Pain Treatment

US Patent 5,475,034 claims a method of treating ophthalmic inflammatory disorders and ocular pain via topical ocular administration of a defined class of 3-benzoylphenylacetic acid derivatives (substituted at specific positions with constrained substituent sets), in anti-inflammatory effective amounts. The claim set is built around (1) the compound structural formula constraints, (2) method use in the ophthalmic pain/inflammation context, (3) narrower dependent selections of compounds, and (4) specific concentration ranges in w/v.

What do the independent claims cover?

Claim 1 (core scope): topical ophthalmic treatment with a formula-defined active

Claim 1 covers:

Use type: “A method of treating ophthalmic inflammatory disorders and ocular pain”
Route: “topically administering to the eye”
Dosage form: “a pharmaceutical composition”
Active class: an “anti-inflammatory-effective amount of a 3-benzoylphenylacetic acid derivative”
Structural constraint: the derivative must fall within the formula labeled STR7, with the following variables:
- R can be:
- H
- C1-4 (un)branched alkyl
- CF3
- SR4
- Y can be:
- NR"R'
- with R' = H or C1-10 (un)branched alkyl
- R" can be H
- X and X' independently can be:
- H, F, Cl, Br, I, OR', OH, SR4, CF3, R4, or NO2
- R4 is C1-6 (un)branched alkyl
- m is 0-3
- m' is 0-5
- W is H

Practical interpretation of breadth: Claim 1 is a formula-first claim. It is not limited to a single drug or a single named embodiment; it captures a range of substitution patterns consistent with the STR7 general structure, with flexibility in:

halogenation (F, Cl, Br, I),
electron-withdrawing groups (CF3, NO2),
oxygen and thioether substituents (OR', OH, SR4),
alkyl chain lengths (R, R', R4; and ring-position ranges m and m').

At the same time, it is constrained by:

R" = H,
W = H,
limited alkyl chain length windows (C1-4 for R; C1-10 for R'; C1-6 for R4),
defined m and m' maxima (m up to 3, m' up to 5).

The claim is anchored to ophthalmic inflammatory disorders and ocular pain. That use language matters for design-around because topical ophthalmic delivery alone may not trigger infringement if the therapeutic indication is not within the claimed treated conditions and the claim is enforced as a method claim.

Claim 2 (tightens within Claim 1’s formula universe)

Claim 2 limits Claim 1 to a narrower subset where the compound is of formula STR8, with:

R = H or C1-2 alkyl
Y = NR'R" where:
- R' = H or C1-6 (un)branched alkyl
X and X' independently = H, F, Cl, Br, CF3, OR', SR4, or R4
R" = H
R4 = C1-4 (un)branched alkyl
m = 0-2
m' = 0-2
W = H

Net effect: Claim 2 reduces scope by restricting substituent positions (m/m'), and reducing alkyl length ceilings (R, R4) versus Claim 1.

Claims 3 to 5 (named-structure selection claims)

These claims do not merely restate the generic formulas; they explicitly list compounds.

Claim 3: selects from a group of 10+ named 2-amino-3-(benzoyl)-α-(alkylthio)-phenylacetamide / related entities, including:
- 2-Amino-3-(4-fluorobenzoyl)-α-(n-propylthio)-phenylacetamide
- 2-Amino-3-benzoyl-α-(n-propylthio)-phenylacetamide
- 2-Amino-3-(4-chlorobenzoyl)-α-(n-propylthio)-phenylacetamide
- 2-Amino-3-benzoyl-5-chloro-α-(methylthio)-phenylacetamide
- 2-Amino-3-(4-fluorobenzoyl)-α-(methylthio)-N-(2-methoxy)ethylacetamide
- 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide
- 2-Amino-3-benzoyl-phenylacetamide
- 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide
- 2-Amino-3-benzoyl-5-chlorophenylacetamide
- 2-Amino-3-(4-bromobenzoyl)-phenylacetamide
- 2-Amino-3-(4-bromobenzoyl)-N-methyl phenylacetamide (as listed in your claim text)
Claim 4: selects from a subset (9 items listed in your text), with overlaps and emphasis on:
- 4-fluoro and 4-chloro benzoyl variants,
- presence of α-(n-propylthio) in certain entries,
- and multiple chloro substitution patterns,
- including several that omit the α-alkylthio motif.
Claim 5: narrows further to three entries:
- 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide
- 2-Amino-3-benzoyl-phenylacetamide
- 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide

Practical inference for infringement mapping: If a product uses one of these specific listed compounds (as an ophthalmic active), the claim pathway is direct via dependent claims. Even if an accused compound misses one substituent rule in Claim 1, it still can land in Claims 3-5 if it matches a listed member.

What is the claimed dosing and how narrow is it?

Claims 6-7 (concentration limits)

Claim 6: “amount of 3-benzoylphenylacetic acid is from about 0.001 to about 4.0% (w/v)”
Claim 7: “amount of 3-benzoylphenylacetic acid is from about 0.01 to about 0.5% (w/v)”

Scope impact:

These are numerical concentration caps tethered to “3-benzoylphenylacetic acid” (not the full derivative class as such). The dependent structure means:
- if enforcement uses Claim 6/7, the accused formulation must fall inside the listed w/v range for the relevant “3-benzoylphenylacetic acid” entity.
For a compound that is a derivative rather than the unsubstituted “3-benzoylphenylacetic acid,” the concentration language can become a factual/legal parsing point in practice (what is “3-benzoylphenylacetic acid” within the formulation). But as written, the dosing claims are clearly tied to that named compound identity.

How does this create a patent landscape risk for topical ophthalmic anti-inflammatories?

Risk profile anchored to four claim elements

US 5,475,034 creates infringement exposure when all of the following align:

Therapeutic use: treatment of ophthalmic inflammatory disorders and ocular pain
Route: topical administration to the eye
Active: a compound that matches the STR7 / STR8 formula constraints or the named listed compounds
Dose (only if asserting Claims 6 or 7): 0.001 to 4.0% w/v or 0.01 to 0.5% w/v for “3-benzoylphenylacetic acid”

Landscape implications for competitors

Design-around on structure: The formula limits in Claim 1 are strong because they specify allowed substituents and ranges (R, R', R4, m, m'). A competitor can reduce risk by using:
- a different core scaffold,
- different positional substitution patterns outside m/m' windows,
- substituents outside allowed sets (for X/X' and R4/R' lengths).
Design-around on active selection: Even with a close scaffold, Claim 3-5 raise risk for any competitor that selects one of the listed compounds verbatim.
Design-around on indication: Because this is a method claim framed by treated conditions, a product with a tightly constrained label that does not include “ocular pain” or “ophthalmic inflammatory disorders” can attempt to avoid literal method coverage, though enforcement is jurisdiction- and evidence-dependent.

Claim strength notes (within the provided record)

The claims are not just broad “class + method.” They combine:

formula definition (chemistry constraint),
ophthalmic method use (therapeutic constraint),
compound lists (fallback coverage),
concentration limits (pharmaceutical constraint).

That combination usually strengthens enforceability because it supplies multiple independent routes to match an accused product.

What coverage do Claims 1-7 collectively give?

Coverage matrix

Claim	What is required to be met	Scope type	Main value in enforcement
1	Any STR7-matching 3-benzoylphenylacetic acid derivative; topical ocular administration; anti-inflammatory effective amount; treats ophthalmic inflammation and ocular pain	Broadest formula coverage	Captures non-listed derivatives within constrained substitution sets
2	STR8 subset of STR7 with narrower R, R', R4 and m/m' limits	Medium coverage	Narrows to a defensible chemical sub-class
3	One of the listed compounds (10+ entries) within STR7/STR8 space	Narrow by identity	Direct hit if a listed member is used
4	Subset of listed compounds	Narrower by identity	Secondary fallback
5	One of 3 specific compounds	Narrowest by identity	Strongest match pathway if those exact compounds appear in products
6	Uses “3-benzoylphenylacetic acid” at 0.001-4.0% w/v	Narrow by dosage	Adds formulation-level constraint
7	Uses “3-benzoylphenylacetic acid” at 0.01-0.5% w/v	Narrowest by dosage	Additional constraint band for product formulation matching

Scope limits and likely “easy outs”

Structural limits that can block infringement

Claim 1’s structural bounds can be used as “stop signs” in freedom-to-operate reviews:

R" is fixed at H
W is fixed at H
m and m' have maximum values (m up to 3; m' up to 5 in Claim 1; tighter in Claim 2)
Alkyl chain windows: R up to C1-4, R' up to C1-10, R4 up to C1-6 (then narrowed in Claim 2)

Method-use limits

“Treating ophthalmic inflammatory disorders and ocular pain” narrows the claim’s therapeutic frame. If a competitor positions therapy under a different functional endpoint (for example, different class of ocular conditions) and the evidence does not show treatment of the claimed disorder set, infringement may fail on method-use elements.

Dosage constraints only apply when the dosing claims are asserted

Claims 6-7 are dependent; if an accused product uses outside the listed w/v windows, Claim 1 or Claim 2 (and identity-based dependent claims) may still remain in play unless the asserted theory is specifically anchored to the concentration limitations.

US patent landscape: what can be concluded from the claim text alone

The provided material is limited to the claim text for US 5,475,034 and does not include bibliographic data (assignee, filing date, publication history), prosecution history, cited references, or related family members. As a result, a complete US landscape mapping (competing patents, expiration risks, citation network, continuation activity, or distinct patent families in the same chemical space) cannot be constructed from the information provided.

Key Takeaways

US 5,475,034 is a topical ophthalmic method-of-treatment patent focused on 3-benzoylphenylacetic acid derivatives with STR7 formula constraints and explicit named compound embodiments.
Claim coverage is layered: formula-first (Claim 1), narrower formula subset (Claim 2), named selections (Claims 3-5), and formulation concentration bands (Claims 6-7).
The main infringement targets in practice are products that use listed compounds or use compounds that fall inside STR7/STR8 substitution limits, with additional leverage if formulation uses 0.01-0.5% w/v or 0.001-4.0% w/v “3-benzoylphenylacetic acid.”
Landscape assessment beyond this claim text requires bibliographic and citation data not included here; the analysis above captures only what can be derived directly from the claims you provided.

FAQs

1) Does US 5,475,034 cover oral administration?
No. The method is explicitly “topically administering to the eye.”

2) Is the patent limited to one active ingredient?
No. Claim 1 covers a class of 3-benzoylphenylacetic acid derivatives meeting STR7 constraints; Claims 3-5 also list specific members.

3) What conditions does the method claim require?
“ophthalmic inflammatory disorders and ocular pain.”

4) How do Claims 6 and 7 affect design-around?
They constrain “3-benzoylphenylacetic acid” concentrations to defined w/v bands, but they are dependent claims.

5) Which claim is the broadest?
Claim 1 is the broadest because it covers the full STR7 formula class plus the ophthalmic method use.

References

[1] US Patent 5,475,034, “Method of treating ophthalmic inflammatory disorders and ocular pain” (claims as provided in the prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0716600	⤷ Start Trial	C00716600/01	Switzerland	⤷ Start Trial
Austria	215366	⤷ Start Trial
Australia	2818495	⤷ Start Trial
Australia	689277	⤷ Start Trial
Canada	2167524	⤷ Start Trial
China	1088992	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,475,034

Summary for Patent: 5,475,034